The ongoing price disclosure system brokered by Medicines Australia and the Government will see another 13 medicines attract significant price cuts ranging from 11 to 77 per cent from August 1 this year.

The medication price cuts are in addition to the broadbrush $1.9 billion in PBS savings that constitute the Memorandum of Understanding (MoU) between Medicines Australia (MA) and the Government, which saw 74 medicines slashed in price last month.

Manufacturers of originators (brand name medicines) are bracing themselves for future price cuts as patents expire and medications become subject to price disclosure.

The 13 medicines, representing more than 200 brands include Amisulpride, Bisoprolol, Cefalotin, Doxorubicin, Escitalopram, Levetiracetam, Meloxicam, Mitozantrone, Ondansetron, Oxaliplatin, Oxybutinin, Perindopril and Prochlorperazine.